Compare Citigroup Inc. (C) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citigroup Inc. vs Novo Nordisk A/S — how do they compare? Citigroup Inc. trades at $136.13 (market cap $227.75B), while Novo Nordisk A/S trades at $45.92 (market cap $207.85B). The key difference: Citigroup Inc. and Novo Nordisk A/S are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| C | NVO | |
|---|---|---|
Market Cap | $227.75B | $207.85B |
Sector | Financials | Health |
52-Week High | $145.67 | $63.98 |
52-Week Low | $92.59 | $35.29 |
Dividend Yield | 1.97% | 3.81% |
Enterprise Value | — | $222.55B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
